公开(公告)号：US11413284B2

公开(公告)日：2022-08-16

申请号：US16646390

申请日：2018-09-11

Applicant: NOVARTIS AG

Inventor： Vesselina Cooke ,  Michael Scott Visser ,  Andrew Wylie ,  Padmaja Yerramilli-Rao ,  Xu Zhu

IPC: A61K31/497 ,  A61P35/00 ,  A61K9/00 ,  A61K45/06

Abstract: The present disclosure relates to use of a protein kinase C (PKC) inhibitor in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments. The disclosure further relates to use of a pharmaceutical combination comprising a PKC inhibitor and another therapeutic agent, such as an MDM2 inhibitor, in the treatment or prevention of a proliferative disease.

公开(公告)号：US12208097B2

公开(公告)日：2025-01-28

申请号：US17808388

申请日：2022-06-23

Applicant: NOVARTIS AG

Inventor： Vesselina Cooke ,  Michael Scott Visser ,  Andrew Wylie ,  Padmaja Yerramilli-Rao ,  Xu Zhu

IPC: A61K31/497 ,  A61K9/00 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure relates to use of a protein kinase C (PKC) inhibitor in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments. The disclosure further relates to use of a pharmaceutical combination comprising a PKC inhibitor and another therapeutic agent, such as an MDM2 inhibitor, in the treatment or prevention of a proliferative disease.

公开(公告)号：US20220364055A1

公开(公告)日：2022-11-17

申请号：US17271430

申请日：2019-08-30

Applicant: Novartis AG

Inventor： Louise Treanor ,  Michael R. Greene ,  Jennifer Brogdon ,  Boris Engels ,  Glenn Dranoff ,  Olja Kodrasi ,  Hyungwook Lim ,  Akash Sohoni ,  Elizabeth Dorothy Pratico ,  Anniesha Hack ,  Aida Abujoub ,  Tony Fleming ,  Lu Huang ,  Connie Hong ,  John Blankenship ,  Brian Holmberg ,  Chonghui Zhang ,  Dexiu Bu ,  Andrew Price ,  Xu Zhu ,  Andrew Stein ,  Attilio Bondanza

IPC: C12N5/0783 ,  A61K35/17 ,  A61K31/519 ,  A61K38/20 ,  C07K16/28 ,  C07K14/705

Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.

公开(公告)号：US20220323436A1

公开(公告)日：2022-10-13

申请号：US17808388

申请日：2022-06-23

Applicant: NOVARTIS AG

Inventor： Vesselina Cooke ,  Michael Scott Visser ,  Andrew Wylie ,  Padmaja Yerramilli-Rao ,  Xu Zhu

IPC: A61K31/497 ,  A61P35/00 ,  A61K9/00 ,  A61K45/06

Abstract: The present disclosure relates to use of a protein kinase C (PKC) inhibitor in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments. The disclosure further relates to use of a pharmaceutical combination comprising a PKC inhibitor and another therapeutic agent, such as an MDM2 inhibitor, in the treatment or prevention of a proliferative disease.

公开(公告)号：US20210220404A1

公开(公告)日：2021-07-22

申请号：US17104983

申请日：2020-11-25

Applicant: Michael R. Greene ,  Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Attilio Bondanza ,  Jennifer Brogdon ,  Dexiu Bu ,  Serena De Vita ,  Glenn Dranoff ,  Boris Engels ,  Tony Fleming ,  Brian Walter Granda ,  Michael R. Greene ,  Carla Patricia Guimaraes ,  Anniesha Hack ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Olja Kodrasi ,  Joni Waiee Lam ,  Hyungwook Lim ,  Elizabeth Dorothy Pratico ,  Andrew Price ,  Akash Sohoni ,  Andrew Marc Stein ,  Louise Treanor ,  Chonghui Zhang ,  Xu Zhu

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395 ,  C07K14/705 ,  A61K38/17 ,  C12N5/0783 ,  C07K14/725

Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.